Oncology market research

  • Promising drugs in the late stage of the pipeline, combined with high potential in emerging economies
  • Strong technological advancements and rising concern over high death rates due to cancer
  • Introduction of new therapies and drugs for cancer and government support to enhance healthcare facilities
  • These companies have a wider geographical presence and are also actively involved in R&D in order to expedite regulatory approval
  • June 2022: The US Food and Drug Administration (FDA) approved Bristol Myers Squibb’s CAR T cell therapy Breyanzi for relapsed or refractory large B-cell lymphoma after one prior therapy
  • May 2022: The FDA approved Merck’s Keytruda for MSI-H, dMMR endometrial cancer and Roche’s CDx
  • Artificial intelligence (AI) and machine learning (ML) will become routine features of patient care: Rapid adoption of virtual modes of care including AI and ML has changed the overall method of patient care and has tremendous potential to reduce waste while driving improvements in evidence-based medicine and more efficient, smarter workflows.
  • New cell and gene therapies: The launch of new modalities including cell therapy, viral vectors, RNA therapy and stem-cell therapies has revolutionised the oncology market and changed the focus of oncologists to a value-based care model. Kymriah and Yescarta, two CAR-T cell therapies, were approved for acute lymphocytic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL). While current CAR-T sales remain modest, several hundred active agents are being tested, with 2024 revenue forecast to surpass USD6bn.
  • Immuno-oncology combination therapies: Increasing investment in immuno-oncology combination studies, with more than 200 mechanisms now being investigated as PD-(L)1 or CTLA-4 combination partners, and immuno-oncology assets estimated to represent approximately half of the top 10 companies’ pipelines. Immuno-oncology (IO) is emerging as a novel approach to cancer treatment through the stimulation of the body’s own immune system. For example, the nivolumab + ipilimumab combination therapy for the treatment of lung cancer and the pembrolizumab + nivolumab combination therapy for the treatment of metastatic melanoma.
  • High costs associated with diagnostic imaging equipment, coupled with capital investment
  • High risk of side effects associated with cancer treatment
  • Stringent government regulations, high cost of drugs and patent expiry

--

--

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Acuity Knowledge Partners

Acuity Knowledge Partners

We write about financial industry trends, the impact of regulatory changes and opinions on industry inflection points. https://www.acuitykp.com/